Pancragen
Pancreas Research only Animal studies Synthetic short peptide (Cytogen)
Also called KEDW peptide
A four-amino-acid Khavinson peptide associated with the pancreas. In aged monkeys it was reported to improve glucose tolerance and insulin response, and in cell studies it supported the maturation of pancreatic cells. It is unrelated to the PancraGEN diagnostic test.
Evidence at a glance
- Evidence
- Animal studies — Not yet studied in people
- Status
- Research compound only
- Dosing
- No human study has set a dose
Animal and cell data from one group.
What studies report
- Improved glucose tolerance and insulin response in aged monkeys
- Supported maturation of pancreatic cells in culture
How it works
A Khavinson short peptide: at two to four amino acids it is small enough to pass through cell and nuclear membranes intact. The proposed mechanism is that it binds specific sites on nuclear DNA and changes which genes are switched on in its target tissue, rather than acting on a surface receptor the way most peptides do.
Where it acts
PancreasThe library groups this compound under Pancreas. The diagram shows that target, not every tissue it reaches.
Illustrated
AI-generated subject illustration; not a depiction of the compound or evidence of its effects.
Why people take it
Reasons people seek it out — not a list of proven effects.
Status: Animal and cell data, mostly from one research group.
- Route
- Subcutaneous injection, or oral capsule depending on the preparation
- Sequence
- Lys-Glu-Asp-Trp
- Formula
- C26H36N6O9
- Molecular weight
- 576.6 g/mol
- Available as
- 20 mg
Search PubMed for Pancragen → We link a live search rather than a fixed citation list, so it stays current and nothing here is a reference we have not checked.
Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.